IRLAB Therapeutics AB (OSTO:IRLAB A) EV-to-EBITDA : -5.03 (As of May. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IRLAB Therapeutics AB's enterprise value is kr758.43 Mil. IRLAB Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-150.67 Mil. Therefore, IRLAB Therapeutics AB's EV-to-EBITDA for today is -5.03.

The historical rank and industry rank for IRLAB Therapeutics AB's EV-to-EBITDA or its related term are showing as below:

OSTO:IRLAB A' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50.72 Med: -14.82 Max: 37.5
Current: -5.03

During the past 11 years, the highest EV-to-EBITDA of IRLAB Therapeutics AB was 37.50. The lowest was -50.72. And the median was -14.82.

OSTO:IRLAB A's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.51 vs OSTO:IRLAB A: -5.03

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), IRLAB Therapeutics AB's stock price is kr15.50. IRLAB Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-3.040. Therefore, IRLAB Therapeutics AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

IRLAB Therapeutics AB EV-to-EBITDA Historical Data

The historical data trend for IRLAB Therapeutics AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB EV-to-EBITDA Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-15.84

-19.76

33.83

-16.04

-1.76

IRLAB Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial															-2.65	-1.89	-1.55	-1.76	-5.08

Competitive Comparison of IRLAB Therapeutics AB's EV-to-EBITDA

For the Biotechnology subindustry, IRLAB Therapeutics AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's EV-to-EBITDA falls into.

IRLAB Therapeutics AB EV-to-EBITDA Calculation

IRLAB Therapeutics AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	758.427	/	-150.67
	=	-5.03

IRLAB Therapeutics AB's current Enterprise Value is kr758.43 Mil.
IRLAB Therapeutics AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-150.67 Mil.

IRLAB Therapeutics AB (OSTO:IRLAB A) EV-to-EBITDA Explanation

IRLAB Therapeutics AB's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	15.50	/	-3.040
	=	At Loss

IRLAB Therapeutics AB's share price for today is kr15.50.
IRLAB Therapeutics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.040.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

IRLAB Therapeutics AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

6IRA:Germany

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines